CRL

Business Profile & Competitive Position

Charles River Laboratories International, Inc. sits in the Healthcare sector, specifically the Medical - Diagnostics & Research industry. The company acts as a full-service, non-clinical global drug development partner, providing research model technologies, discovery and safety assessment services (both GLP and non-GLP), and manufacturing support. It reports through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025 total revenue was $4.0 billion, with DSA contributing 59.8% of that total, RMS 21.1%, and Manufacturing 19.1%. The company runs more than 120 sites across over 20 countries.

The margin and return figures, however, do not point to a deep or durable moat. Net margin is -6.0%, ROE is -7.7%, and the trailing P/E is -59.3, all showing the company is currently losing money and generating negative returns for shareholders. A strong competitive moat usually supports repeatable, positive economic returns; these negative numbers instead suggest that pricing power is constrained and that the current cost structure is absorbing more value than the business is producing. Right now, the data imply CRL is defending its place in the non-clinical services chain rather than extracting excess economic profit from it.

Financial Posture

As of the 2026-08-17 snapshot, CRL had a market capitalization of $13.8 billion and traded at $286.79. A P/E of -59.3 means there are no trailing earnings to support a traditional valuation multiple. The -6.0% net margin and -7.7% ROE reinforce that the business is currently in the red.

The stock is also more volatile than the broad market, carrying a beta of 1.38. Momentum indicators show a sharp run-up: price is at $286.79, well above the 50-day EMA of $231.47, and the RSI reads 78.4, a level typically associated with strong near-term momentum and potential overbought conditions. The valuation therefore reflects a market looking past the current loss, but the negative profitability and return figures mean execution risk remains high.

Strategic Priorities & Outlook

Charles River’s most recent 10-K outlines an operational agenda built around footprint optimization, organizational simplification, and targeted expansion. Management plans to close or consolidate approximately 12 additional sites over the next two years, principally within DSA and RMS, while integrating Discovery Services and Safety Assessment into a single DSA organization with a combined sales force and leadership structure. The company also aims to expand its Biologics Testing Solutions service offerings and facilities in the U.S. and Europe, and to position itself as the scientific partner of choice through a comprehensive, integrated portfolio.

In January 2026, the company acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. That deal aligns with the broader priority of securing research-model supply chains. Taken together, the strategy points to cost rationalization (fewer sites), go-to-market integration (one DSA team), and supply assurance for the animal models that feed the safety assessment business.

Macro & Geopolitical Exposure

As a non-clinical drug development services provider in the Medical - Diagnostics & Research industry, CRL’s demand is tied to biopharmaceutical R&D budgets. When biotech funding tightens or large pharma slows pipeline investment, discovery, safety assessment, and manufacturing support spending can soften. The industry is also exposed to regulatory risk: GLP and non-GLP studies must satisfy FDA, EMA, and other agency standards, and changes in animal-research regulation could raise costs or constrain model supply.

Because the company operates in more than 20 countries, currency translation and cross-border staffing are ongoing considerations. Trade policy matters too: research models and biological materials move globally, and the Cambodia acquisition highlights the importance of non-human primate sourcing. Commodity-like inputs such as animal feed, reagents, and lab consumables can pressure margins, while public and political sentiment around animal testing creates headline risk. In short, the sector’s health depends on R&D spending, a permissive regulatory environment, and stable global supply chains.

Recent Developments

Recent headlines have focused on price momentum, international reach, and insider activity. On 2026-08-11 defenseworld.net reported that CAO Michael Gunnar Knell sold 6,645 shares. The same source noted the same day that Charles River Laboratories International (NYSE:CRL) had set a new 52-week high. On 2026-08-10, zacks.com published “International Markets and Charles River (CRL): A Deep Dive for Investors,” suggesting renewed attention to the company’s global footprint. Earlier, on 2026-08-06, 247wallst.com included CRL among “Thursday’s Top Wall Street Analyst Research Calls” alongside AppLovin, Global Payments, HubSpot, and others.

The insider sale and the new 52-week high arriving together reflect the tension between strong stock performance and executive-level distribution. The timing also coincides with an RSI of 78.4 and a price roughly $55 above the 50-day EMA of $231.47, underscoring how fast the stock has moved.

Earnings Behavior & Post-Earnings Drift

Charles River has beaten consensus earnings estimates in all of the last eight reported quarters, a 100% beat rate, with an average positive surprise of 9.3%. Across those same quarters the average five-day post-earnings drift has been 1.24%, classified as upward drift.

The last four reports show that beats were consistent, but price reactions varied. For the 2026-08-05 quarter CRL reported $3.02 per share versus a $2.74 estimate, a 10.2% surprise; the stock rose 1.84% the next day and 9.07% over the following five sessions. The prior quarter, reported on 2026-05-07, produced $2.06 versus $1.96, a 5.1% beat, yet the stock fell 2.23% the next day and 12.42% over the following five days. On 2026-02-18 the company delivered $2.39 against $2.33, a 2.6% surprise, and the stock rose 3.95% the next day and 6.05% over five days. The 2025-11-05 report showed $2.43 versus $2.32, a 4.7% surprise, with gains of 1.9% the next day and 2.27% over five days.

That divergence suggests the unofficial consensus can exceed the published estimate, and that guidance or commentary sometimes matters more than the headline beat. The next scheduled report is on 2026-11-04 before the market open, with the current consensus EPS estimate at $2.97. Given the 100% beat streak, the market will likely judge the quarter against that $2.97 figure and any forward outlook management provides.

For a deeper dive into CRL’s institutional rating, analyst consensus, and forward estimates, consider reviewing the full institutional verdict on the company.